KPV peptide: FDA status, legal access, dosage and side effects
What KPV is, what changed in October 2026, and what the research does and does not show.
KPV is a three-amino-acid peptide (lysine-proline-valine), the tail end of the hormone alpha-MSH, studied in cell and mouse research on inflammation signaling. It is not FDA-approved. Since HHS’s October 30, 2026 interim policy, a licensed 503A pharmacy may compound it, topical or oral, on a patient-specific prescription. REMEVi does not currently offer KPV.
KPV is not FDA-approved. Since HHS’s October 2026 interim policy, a state-licensed 503A pharmacy may compound it on a patient-specific prescription under listed conditions.
REMEVi does not currently offer KPV.
What changed in 2026
On October 30, 2026, HHS published an interim enforcement-discretion policy for 503A compounding (Federal Register, October 30, 2026). It says HHS does not intend to take enforcement action against a state-licensed pharmacy or federal facility that compounds one of six listed peptides, KPV among them, while the 503A bulks list is developed through rulemaking.
For KPV, the policy lists two routes: topical and oral. Every condition must be met:
- A patient-specific prescription from a licensed prescriber.
- KPV acetate, compounded for a topical or oral route — no other route is covered.
- One active ingredient per product. A product that combines KPV with another peptide is outside the policy.
- Bulk KPV from an FDA-registered facility with a valid certificate of analysis (CoA); the original manufacturer FDA-registered and CGMP-compliant.
- For oral KPV, the compounding pharmacy must keep documentation that the formulation is adequately bioavailable in humans.
- No device packaged with the drug other than an FDA 510(k)-cleared syringe.
- The label reads “This is a compounded drug product. Not for resale.”
- Serious adverse events are reported to FDA MedWatch.
The policy is interim and revocable. HHS says it may revisit it if a safety signal or product quality issue arises, and that it is not binding. It is not FDA approval, it does not add KPV to the 503A bulks list, and it covers 503A compounding, not 503B outsourcing facilities. Comments were open for two weeks after publication (docket HHS-OASH-2026-0496).
Read the Federal Register notice · The policy explained in plain words
The other five peptides the policy lists:
How a legal KPV prescription works
- A licensed prescriber evaluates you and decides whether KPV is appropriate. That decision belongs to the prescriber, not to a website.
- If it is, they write a prescription for you by name, for a topical or oral KPV product.
- A state-licensed 503A pharmacy compounds it from registered, CoA-documented bulk KPV, with KPV as the single active ingredient.
- The product arrives labeled “This is a compounded drug product. Not for resale.”
- Any serious adverse event is reported to FDA MedWatch.
Research-grade vials vs compounded prescriptions
Products sold online as “for research use only” are not compounded prescriptions and fall outside the HHS policy. They are not made for a named patient, nothing requires a registered source or a certificate of analysis, and nobody is checking oral bioavailability. On August 24, 2026, FDA sent warning letters to five online peptide vendors; according to Holland & Knight, FDA found that “research use only” labels did not outweigh evidence the products were intended for people.
What research exists on KPV
Almost all KPV research is in cells and mice. We found no published study that measured a health outcome of KPV given to people (PubMed, checked November 2, 2026). That means there is little or no human outcome data, and mouse or cell findings may not carry over to humans.
- Gut, mouse and cell: Dalmasso et al. (Gastroenterology, 2008) showed intestinal and immune cells take up KPV through the PepT1 transporter, and studied oral KPV in drinking water in mouse colitis models.
- Gut, mouse: Kannengiesser et al. (Inflammatory Bowel Diseases, 2008) studied KPV in two mouse colitis models.
- Gut, mouse: Xiao et al. (Molecular Therapy, 2017) packaged KPV in nanoparticles given by mouth to mice with chemically induced colitis.
- Skin, mouse: Hiltz and Lipton (FASEB Journal, 1989) studied the alpha-MSH 11–13 fragment in a mouse ear-swelling model of contact dermatitis.
- Skin, human cells: Elliott et al. (Journal of Investigative Dermatology, 2004) measured how human keratinocytes signal in response to KPV in the lab.
KPV side effects: the short version
Because there are no published human trials of KPV, its side effects in people are not known. Animal papers focus on inflammation measures rather than a safety profile. Tell a licensed provider about pregnancy, breastfeeding, cancer history, allergies and every medicine you take.
KPV dosage: the short version
We found no published human dose for topical or oral KPV. The doses in the literature come from mice and are not human doses. Published protocols vary; a licensed provider sets your dose; never self-dose.
KPV cost: the short version
Published figures for compounded KPV vary by program type, and most were published before the October 2026 policy. REMEVi does not currently price KPV.
Has the FDA approved KPV?
No. KPV is not FDA-approved for any use. Since October 30, 2026, an interim HHS policy lets a state-licensed 503A pharmacy compound topical or oral KPV on a patient-specific prescription under listed conditions. That policy is enforcement discretion, not approval, and HHS can revisit it if a safety or quality issue arises.
What is KPV peptide used for?
KPV has no approved use. It has been studied for inflammation signaling, mainly in mouse models of colitis and in skin-inflammation models and skin cells. Those studies do not show that KPV treats any condition in people, because published human outcome studies of KPV were not found. A licensed provider decides whether it fits you.
Can you take KPV orally?
Oral KPV is one of the two routes HHS’s 2026 policy lists, alongside topical. The policy adds a condition: the compounding pharmacy must keep documentation that the oral formulation is adequately bioavailable in humans. Oral KPV research so far is in mice, given in drinking water or in nanoparticles, not in people.
Is KPV a steroid?
No. KPV is a peptide: a chain of three amino acids, lysine, proline and valine, matching positions 11 to 13 of the hormone alpha-MSH. Steroids are a different chemical class built on a ring structure. The 1989 mouse study that described KPV’s anti-inflammatory activity compared it with a corticosteroid, but KPV is not one.
Sources
- HHS, Federal Register — Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (91 FR 68526, October 30, 2026) (read November 2, 2026)
- Holtz, Beaver & Rosen (Foley & Lardner), National Law Review, Oct 30, 2026 — HHS Announces Limited Enforcement Discretion for Compounding of Six Peptides (read November 2, 2026)
- Bigica, Nutritional Outlook, Nov 2, 2026 — What the Interim Compounding Pathway for Peptides Could Mean for Supplement Brands (read November 2, 2026)
- Holland & Knight, Oct 16, 2026 — Peptides at a Crossroads: What Wellness Providers Need to Know About HHS and FDA Actions (read November 2, 2026)
- Dalmasso et al., Gastroenterology 2008 — PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation (read November 2, 2026)
- Kannengiesser et al., Inflammatory Bowel Diseases 2008 — Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease (read November 2, 2026)
- Xiao et al., Molecular Therapy 2017 — Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis (read November 2, 2026)
- Hiltz & Lipton, FASEB Journal 1989 — Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH (read November 2, 2026)
- Elliott et al., Journal of Investigative Dermatology 2004 — Alpha-melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells (read November 2, 2026)
Medically reviewed by Linda West-Conforti, RN · CA RN #389453 ·